Alembic Limited has announced its audited financial results for the quarter and financial year ended 31st March, 2026. The Board of Directors has recommended a dividend of Rs. 2.40 per equity share (120%) for the financial year 2025-26. The company’s revenue from operations for the quarter ended 31st March, 2026 stood at Rs. 60.04 Crores, compared to Rs. 74.34 Crores in the previous quarter and Rs. 60.27 Crores in the corresponding quarter of the previous year. The profit before tax for the quarter ended 31st March, 2026 was Rs. 18.44 Crores (derived from total income of Rs. 62.18 Crores minus total expenses of Rs. 43.74 Crores).

Export to Sheets

Alembic Limited, established in 1907 and headquartered in Vadodara, Gujarat, is a conglomerate with a diversified business portfolio. The company operates across several key sectors, including pharmaceuticals, real estate, and power assets. Following a demerger in 2010, the company’s core pharmaceutical formulation business was transitioned into a separate entity, Alembic Pharmaceuticals Ltd., though Alembic Limited continues to maintain significant investments in group entities.